December 29, 2021 Non Regulatory LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
December 20, 2021 Non Regulatory LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
December 17, 2021 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in China
November 17, 2021 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
November 15, 2021 Regulatory LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
October 4, 2021 Regulatory NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
September 28, 2021 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
June 2, 2021 Regulatory LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
June 1, 2021 Regulatory LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer
May 28, 2021 Non Regulatory LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna
April 16, 2021 Non Regulatory Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
April 8, 2021 Non Regulatory International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
March 2, 2021 Regulatory LIDDS enters R&D agreement with potential exclusive, global product license option
February 24, 2021 Non Regulatory LIDDS files patent application for method to treat brain cancer with intratumoral depot injections
February 4, 2021 Non Regulatory European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot